CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: Clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone

Journal of the Neurological Sciences

Volumn 167, Issue 2, 1999, Pages 79-89

  Boylan, M T ^a   Crockard, A D ^b   McDonnell, G V ^b   Armstrong, M A ^a   Hawkins, S A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

B cells; CD28; CD80; CD86; Costimulation; Methylprednisolone; Monocytes; Multiple sclerosis

Indexed keywords

ANTIGEN; GAMMA INTERFERON; MEMBRANE RECEPTOR; METHYLPREDNISOLONE; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEMORY CELL; MONOCYTE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON TYPE II; MALE; MEMBRANE GLYCOPROTEINS; METHYLPREDNISOLONE; MONOCYTES; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 0032801739     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00132-X     Document Type: Article

References (42)

1. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302.
2. Reiser H., Stadecker M.J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. New Eng J Med. 335:1996;1369-1377.
3. Windhagen A., Newcombe J., Dangond F., et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med. 182:1995;1985-1996.
4. Dangond F., Windhagen A., Groves C.J., Hafler D.A. Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity. J Neuroimmunol. 76:1997;132-138.
5. Kuchroo V.K., Das M.P., Brown G.A., et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;7-18.
6. Racke M.K., Scott D.E., Quigley L., Gray G.S., Abe R., June C.H., Perrin P.J. Distinct roles for B7-1 (CD80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest. 96:1995;2195-2203.
7. Perrin P., Scott D., Davis T.A., et al. Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. J Neuroimmunol. 65:1996;31-39.
8. Schweitzer A.N., Boriello F., Wong R.C.K., Abbas A., Sharpe A. Role of costimulators in T cell differentiation. Studies using antigen-presenting cells lacking expression of CD80 or CD86. J Immunol. 158:1997;2713-2722.
9. Sholz C., Patton K.T., Anderson D.E., Freeman G.J., Hafler D. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol. 160:1998;1532-1538.
10. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients - A marker of activated/memory T cells. J Clin Invest. 101:1998;725-730.
11. Burns J., Bartholomew B., Lobo S. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann Neurol. 45:1999;33-39.
12. McDonnell G.V., Hawkins S.A. Clinical study of primary progressive multiple sclerosis in Northern Ireland. J Neurol Neurosurg Psychiatry. 64:1998;451-454.
13. Thompson A.J., Kermode A.G., MacManus D.G., et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br Med J. 300:1990;631-634.
14. Thompson A.J., Kermode A.G., Wicks D., et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 29:1991;53-62.
15. Revesz T., Kidd D., Thompson A.J., Barnard R.O., McDonald W.I. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 117:1994;759-765.
16. Giovannoni G., Thorpe J.W., Kidd D., et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry. 60:1996;20-26.
17. McDonnell G.V., McMillan S.A., Douglas J.P., Droogan A.G., Hawkins S.A. Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. J Neuroimmunol. 85:1998;186-192.
18. Olerup O., Hillert J., Fredrikson S., et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA. 86:1989;7113-7117.
19. Hillert J., Grönning M., Nyland H., Link H., Olerup O. An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 55:1992;887-890.
20. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
21. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
22. Liu M.F., Kohsaka H., Hiroshi S., et al. The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum. 39:1996;110-114.
23. Tandon N., Metcalfe R.A., Barnett D. Expression of the costimulatory molecule B7/BB1 in autoimmune thyroid disease. Quart J Med. 87:1994;231-236.
24. Folzenlogen D., Hofer M.F., Leung D.Y.M., Freed J.H., Newell M.K. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immun Immunopath. 83:1997;199-204.
25. Liu M.-F., Li J.-S., Weng H.-Y. Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus. Scand J Immunol. 49:1999;82-87.
26. McDonnell G.V., Hawkins S.A. An epidemiological study of multiple sclerosis in Northern Ireland. Neurology. 50:1998;423-428.
27. De Simone R., Giampaolo A., Gionetta B., et al. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J Neuropath Exp Neurol. 54:1995;175-187.
28. Williams K., Ulvistad E., Antel J.P. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur J Immunol. 24:1994;3031-3037.
29. Svenningsson A., Dotevall L., Stemme S., Andersen O. Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. J Neuroimmunol. 75:1997;59-68.
30. Genç K., Dona D.L., Reder A.T. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon-β 1a therapy. J Clin Invest. 99:1997;2664-2671.
31. Freeman G.J., Boussiotis V.A., Anumanthan A., et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 2:1995;523-532.
32. Croft M., Bradley L.M., Swain S.L. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol. 152:1994;2675-2685.
33. Kundig T.M., Bachmann M.F., Oehen S., et al. On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci USA. 93:1996;9716-9723.
34. Riekmann P., Albrecht M., Kitze B., et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology. 44:1994;1523-1526.
35. Frequin S.T.F.M., Lamers K.J.B., Barkhof F., Borm G.F., Hommes O.R. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurol Scand. 90:1994;105-110.
36. Gasperini C., Pozzilli C., Bastianello S., et al. The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longtitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurol Scand. 95:1997;201-207.
37. Barkhof F., Hommes O.R., Sheltens P., Valk J. Quantitative MRI changes in gandolinium-DTPA enhancement after high dose intravenous methylprednisolone treatment in multiple sclerosis. Neurology. 41:1991;1219-1222.
38. Crockard A.D., Treacy M.T., Droogan A.G., McNeill T.A., Hawkins S.A. Transient immunmodulation by intravenous methylprednisolone treatment of multiple sclerosis. Multiple Sclerosis. 1:1995;20-24.
39. Crockard A.D., Treacy M.T., Droogan A.G., Hawkins S.A. CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses. IL-2 and γ-interferon production during intravenous methylprednisolone treatment of multiple sclerosis. J Neurol. 243:1996;475-481.
40. Crockard A.D., Treacy M.T., Droogan A.G., Hawkins S.A. Methylprednisolone attenuates interferon-β induced expression of HLA-DR on monocytes. J Neuroimmunol. 70:1996;29-35.
41. Crockard A.D., Boylan M.T., Droogan A.G., McMillen S.A., Hawkins S.A. Methylprednisolone-induced neutrophil leukocytosis-down-modulation of neutrophil L-selectin and Mac-1 expression and induction of granulocyte-colony stimulating factor. Int J Clin Lab Res. 28:1998;110-115.
42. Fleischer E., Soeth N., Reiling E., Grace-Griebenow E., Flad H.-D., Ernst M. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology. 89:1996;592-598.